glp 1 class drugs What to Make of the GLP-1 Coverage and Cost Landscape A Big Week for GLP-1

This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health

Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer, semaglutide a potential treatment for serious weight gain from ALK tyrosine kinase inhibitors

Probiotics can be part of a broader strategy to create a natural alternative to GLP1 via microbiome modulation, especially alongside fermentable fiber

This is thought to be mediated by direct GLP-1 receptor stimulation in the sinoatrial node

more studies are needed